Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ergo Science Ergoset

Executive Summary

Ortho-McNeil will market bromocriptine mesylate and other products developed by the companies for Type 2 diabetes and obesity in the U.S. and J&J companies will market products worldwide under an agreement announced Feb. 24. Ergo will receive $40 mil. in payments and equity and share equally in costs and profits. The NDA for dopamine-receptor agonist Ergoset was filed in October...
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS031745

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel